Aerie Pharmaceuticals Incの収入
Aerie Pharmaceuticals Incの収入 は何ですか。
Aerie Pharmaceuticals Incの収入 は-36.56$です。
収入 の定義は何ですか。
普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
NASDAQのセクタHealth Careにおける収入 の企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似の収入
- Twintek Investmentの収入 は-36.72HKD$です。
- Simplicityの収入 は-36.69HKD$です。
- Mack-Cali Realtyの収入 は-36.65$です。
- SPI Co Ltdの収入 は-36.60$です。
- Zelira Therapeuticsの収入 は-36.58AUD$です。
- Thunder Bridge Acquisition II Ltdの収入 は-36.56$です。
- Aerie Pharmaceuticals Incの収入 は-36.56$です。
- Eagle Bancorp Inc (MD)の収入 は-36.53$です。
- Novanの収入 は-36.52$です。
- Wai Chunの収入 は-36.52HKD$です。
- BlackRock Debt Strategies Fundの収入 は-36.52$です。
- Ontrak Incの収入 は-36.52$です。
- boohoo group Plcの収入 は-36.50£です。